Latest news with #AUSTIN
Yahoo
10 hours ago
- Business
- Yahoo
Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
AUSTIN, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the Company to initiate its Phase 2 'RENEW' clinical trial of LTI-03, the Company's lead drug candidate for idiopathic pulmonary fibrosis (IPF). IPF is a serious, progressive lung disease that affects hundreds of thousands of people worldwide. It scars the lungs, leaving patients short of breath and with limited treatment options. Median survival after diagnosis is just 3–5 years. Rein's LTI-03 is a first-in-class therapy that is designed to directly target fibrosis while also protecting the lung's ability to regenerate healthy tissue. If successful, it could represent a major breakthrough in how pulmonary fibrosis is treated. Brian Windsor, Chief Executive Officer of Rein Therapeutics, commented, 'This MHRA approval marks an important milestone not only for Rein, but also for patients living with IPF. We are now working towards patient recruitment in the U.K., advancing LTI-03 into the next stage of development. Our approach is designed not only to slow disease progression, but also to preserve, and potentially restore, the lung cells that are critical to everyday breathing and quality of life. We believe LTI-03 has the potential to transform outcomes for patients while also creating substantial value for our shareholders.' Next Steps The RENEW trial is expected to enroll up to 120 patients worldwide, evaluating two dose groups of LTI-03 against a placebo. The primary objective of the trial is to assess safety and tolerability over 24 weeks of treatment. Secondary endpoints will include measures of lung function and imaging-based assessments of fibrosis progression. Rein is actively working with clinical sites in the UK to begin patient recruitment soon, with initial data expected in 2026. About Rein Therapeutics Rein Therapeutics is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Rein's lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 has received Orphan Drug Designation in the U.S. and is in clinical development. Rein's second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the U.S. and E.U. and Fast Track Designation in the U.S. Forward-Looking Statements This press release may contain forward-looking statements of Rein Therapeutics, Inc. ("Rein", the "Company", "we", "our" or "us") within the meaning of the Private Securities Litigation Reform Act of 1995, including statements with respect to expectations for the Company's LTI-03 product candidate, the planned UK Phase 2 clinical trial of LTI-03 and the initial data readouts from the planned UK clinical trial. We use words such as "anticipate," "believe," "estimate," "expect," "hope," "intend," "may," "plan," "predict," "project," "target," "potential," "would," "can," "could," "should," "continue," and other words and terms of similar meaning to help identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including (i) the risk that the Company may not be able to successfully undertake the planned UK Phase 2 clinical trial of LTI-03, (ii) success in early phases of pre-clinical and clinicals trials do not ensure later clinical trials will be successful; (iii) the risk that the Company may not be able to obtain additional working capital with which to initiate and complete planned UK clinical trial, (iv) the risk that the Company may not be able to announce initial data readouts from the planned UK clinical trial in 2026 or, if it is able to do so, that the data may not be favorable and (v) those other risks disclosed in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2024, which is on file with the United States Securities and Exchange Commission (the "SEC") and in subsequent filings that the Company files with the SEC. These forward-looking statements should not be relied upon as representing the Company's view as of any date after the date of this press release, and we expressly disclaim any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Rein Investor Relations & Media Contact: Investor Relations IR@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29-07-2025
- Business
- Yahoo
Natera Announces Launch of ABCSG 61 ("TEODOR"), a Randomized Controlled Trial of Signatera™ in Early-Stage Breast Cancer
Study utilizes Signatera to identify HR+, HER2-negative breast cancer patients for de-escalation of neoadjuvant chemotherapy AUSTIN, Texas, July 29, 2025--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of the TEODOR trial (Neoadjuvant TrEatment Optimization driven by ctDNA and endOcrine Responsiveness). TEODOR is a Phase II, multicenter, randomized controlled trial (RCT) that aims to replace chemotherapy with endocrine therapy prior to surgery for a subset of women with hormone receptor-positive (HR+), HER2-negative breast cancer, who are endocrine responsive and test negative with Signatera. Sponsored by the Austrian Breast & Colorectal Cancer Study Group (ABCSG), TEODOR expects to enroll approximately 250 patients across 15 sites in Austria. Previous studies have demonstrated that patients who test Signatera-negative at diagnosis and then receive chemotherapy have excellent outcomes, with risk of recurrence at less than 5%. In an effort to reduce pre-operative chemotherapy, which can carry significant side effects, this study is designed to evaluate the efficacy of endocrine therapy compared to chemotherapy in patients who are Signatera-negative. After a four-week course of endocrine therapy, patients who are Signatera-negative and show a favorable endocrine sensitivity as measured by the Ki-67 proliferation index will be randomized to receive either additional endocrine therapy or chemotherapy. The primary endpoint of the study is the rate of neoadjuvant therapy response, assessed via pathological complete response (pCR) and modified Preoperative Endocrine Prognostic Index (PEPI) score across the endocrine therapy and chemotherapy arms of the trial. Secondary endpoints include long-term outcomes such as breast cancer recurrence and overall survival. "TEODOR is designed to examine whether we can use endocrine responsiveness and ctDNA status to optimize systemic therapy in the neoadjuvant setting," said ABCSG President, Michael Gnant, M.D., FACS, FEBS, who serves as professor of surgery, Comprehensive Cancer Center, Medical University of Vienna, and principal investigator of the TEODOR trial. "This study marks a critical step toward more personalized medicine, leveraging the latest technologies to improve patient care." "With the TEODOR trial, our goal is to identify patients who may be able to safely forgo chemotherapy," said Angel Rodriguez, M.D., medical director of oncology at Natera. "We are proud to collaborate with ABCSG on this important trial, and we hope this study will support the role of Signatera in guiding neoadjuvant therapy in breast cancer." About Natera Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are supported by more than 300 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit About ABCSG The ABCSG (Austrian Breast & Colorectal Cancer Study Group) is Austria's largest and best-known academic research organization, successfully conducting international clinical trials on breast and colorectal cancer — and, since 2013, also on pancreatic cancer. In addition, ABCSG is increasingly active in translational research. Our goal is to standardize diagnostics, treatment, and follow-up care throughout Austria and to offer patients the best and most up-to-date therapies. Since 1984, approximately 29,000 patients have participated in ABCSG studies worldwide. Multidisciplinarity is key to our global success and has helped improve cure rates and survival. Our clinical trials and translational research projects are conducted transparently and are monitored at every stage by ethics committees, regulatory authorities, and our highly professional and dedicated ABCSG team. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at and View source version on Contacts Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@ Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@ Sign in to access your portfolio
Yahoo
16-07-2025
- Business
- Yahoo
CrowdStrike Brings Agentic AI Security Workflow Integrations and GenAI Protection to AWS Marketplace
falcon-mcp and AI Red Team Services now available in new AI Agents and Tools category of AWS Marketplace AUSTIN, Texas, July 16, 2025--(BUSINESS WIRE)--AWS Summit NYC – CrowdStrike (NASDAQ: CRWD) today announced an expanded collaboration with Amazon Web Services (AWS) to accelerate AI adoption in cybersecurity and secure AI use. With the availability of falcon-mcp, an MCP server for the CrowdStrike Falcon® platform, and CrowdStrike AI Red Team Services in the new AI Agents and Tools category of AWS Marketplace, AWS customers can securely operationalize agentic AI workflow integrations, and test, validate, and protect GenAI systems – all within their existing AWS environment. AI adoption is accelerating, yet most enterprises still lack secure, scalable ways to connect models to real-time security operations. Without trusted frameworks for integration and testing, agentic innovation can introduce new risks. With falcon-mcp and AI Red Team Services now available in the AI Agents and Tools category in AWS Marketplace, organizations can power security operations with AI – and protect the AI systems those operations rely on. "Agentic AI is fundamentally changing business of all sizes across every industry – but only secure AI can safely scale to deliver long-term results," said Daniel Bernard, chief business officer, CrowdStrike. "With these offerings now available in AWS Marketplace, CrowdStrike is giving customers the power to safely build, test, and run AI-driven security workflows using the same cybersecurity platform trusted to protect the world's most critical environments." "As AI becomes embedded across enterprise workflows, the security risks tied to LLMs and agentic platforms are quickly moving from theoretical to practical," said Jay McBain, chief analyst, Canalys. "CrowdStrike's work with AWS – bringing both real-time security integration and proactive AI system validation to the Marketplace – sets a new bar for how the ecosystem can operationalize AI securely at scale." Build Agentic Workflows Securely with falcon-mcp With the launch of falcon-mcp, an MCP server for Falcon platform, CrowdStrike is delivering a standardized, open protocol that securely connects AI agents and LLM-powered applications to Falcon telemetry – including detections, incidents, threat intelligence, and behavioral data. Now available in preview via Amazon Bedrock AgentCore, falcon-mcp simplifies deployment and accelerates adoption of agentic workflows by providing plug-and-play access to Falcon data, enabling seamless integration of AI capabilities into existing security operations – streamlining adoption of secure, agentic workflows. Test and Harden GenAI Systems with AI Red Team Services CrowdStrike AI Red Team Services provide organizations with comprehensive security assessments for AI systems, including LLMs and their integrations, to identify vulnerabilities and misconfigurations that could lead to data breaches, unauthorized code execution, or application manipulation. These assessments align with frameworks like the OWASP Top 10 for LLMs, delivering clear, actionable guidance to harden both AI models and the infrastructure they rely on. Secure End-to-End AI Innovation with CrowdStrike and AWS CrowdStrike and AWS enable joint customers to protect AI applications, services, and LLMs in the cloud. With native integrations across AWS services – including Amazon SageMaker and Amazon Bedrock – customers can deploy and scale AI workloads securely across the entire lifecycle. CrowdStrike delivers purpose-built security for AI through innovations like AI Security Posture Management (AI-SPM), Falcon Data Protection, and AI Red Team Services. Just as AWS relies on the Falcon® platform to protect its own infrastructure – from code to cloud, and device to data – organizations trust CrowdStrike to secure the infrastructure powering the next wave of AI innovation on AWS. To learn more about the CrowdStrike-AWS partnership, visit CrowdStrike at AWS Summit NYC Booth #842. Disclaimer: This press release contains information about developing products and services, including products in public preview and under active development. These offerings including the release timing and features are subject to change at CrowdStrike's sole discretion at any time. About CrowdStrike CrowdStrike (NASDAQ: CRWD), a global cybersecurity leader, has redefined modern security with the world's most advanced cloud-native platform for protecting critical areas of enterprise risk – endpoints and cloud workloads, identity and data. Powered by the CrowdStrike Security Cloud and world-class AI, the CrowdStrike Falcon® platform leverages real-time indicators of attack, threat intelligence, evolving adversary tradecraft and enriched telemetry from across the enterprise to deliver hyper-accurate detections, automated protection and remediation, elite threat hunting and prioritized observability of vulnerabilities. Purpose-built in the cloud with a single lightweight-agent architecture, the Falcon platform delivers rapid and scalable deployment, superior protection and performance, reduced complexity and immediate time-to-value. CrowdStrike: We stop breaches. Learn more: Follow us: Blog | X | LinkedIn | Facebook | Instagram Start a free trial today: © 2025 CrowdStrike, Inc. All rights reserved. CrowdStrike and CrowdStrike Falcon are marks owned by CrowdStrike, Inc. and are registered in the United States and other countries. CrowdStrike owns other trademarks and service marks and may use the brands of third parties to identify their products and services. View source version on Contacts Media Contact Jake SchusterCrowdStrike Corporate Communicationspress@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-07-2025
- Business
- Yahoo
BigCommerce Scores 24/24 Total Medals in 2025 Paradigm B2B Combine Midmarket and Enterprise Editions for Third Consecutive Year
Company scores more gold medals than other platforms in the Midmarket Edition and receives accolades for its vision & strategy, total cost of ownership, ability to execute, customer support and more AUSTIN, Texas, July 16, 2025 (GLOBE NEWSWIRE) -- BigCommerce (Nasdaq: BIGC), a leading open SaaS ecommerce platform for B2C and B2B brands, retailers, manufacturers and distributors, today announced it has scored 24 out of 24 total medals in the 2025 Paradigm B2B Combines for Digital Commerce Solutions (Enterprise and Midmarket Editions) for the third consecutive year. BigCommerce advanced its rankings in five categories in both Editions and achieved more Gold medals in Midmarket than other platforms, further positioning BigCommerce as a preferred choice for midmarket and enterprise B2B organizations looking to improve operational efficiency and grow faster. BigCommerce B2B Edition empowers manufacturers, distributors, and wholesalers to scale efficiently by streamlining operations, reducing costs, and increasing revenue across every channel. Merchants can easily personalize catalogs, pricing, quotes and payment options for each buyer, while integrating seamlessly with leading ERPs, PIMs and CRMs to maintain synchronized data. Building on this foundation, newly launched features, including Configure-Price-Quote (CPQ) and Advanced Account Hierarchy with role-based permissions, further simplify complex account structures, accelerate quote-to-cash cycles and deliver intuitive self-service experiences that deepen customer loyalty and drive long-term growth. 'B2B ecommerce isn't just a channel; it is critical infrastructure,' said Lance Owide, general manager of B2B at BigCommerce. 'For manufacturers and distributors, it's now a core growth lever. The ability to offer buyers a self-service experience, where they can easily find products, place orders, manage accounts and access real-time information, is a competitive requirement. It is how businesses scale without scaling cost. That's why BigCommerce is doubling down on capabilities that help businesses operationalize and unlock the full potential of digital B2B.' 'BigCommerce's B2B Edition has transformed the way we operate as a leading manufacturer and omnichannel distributor of replacement hardware in the Home Improvement space,' said Wilt Kishimoto, director of marketing at 'It's a comprehensive, out-of-the-box solution that is a big contributor to our growth by enabling us to deliver tailored brand storefronts that reflect buyer expectations. The ability to track and analyze performance across all storefronts, or drill down into one, gives us unmatched operational insight. When paired with the buyer portal, we're offering our trading partners and procurement teams a best-in-class experience so they can independently manage quotes, orders, replenishment lists, invoices and logistics all in one centralized hub. B2B Edition has taken the complexity out of scaling. Its flexibility and power are exactly what our industry demands.' BigCommerce received 12 medals in the Paradigm B2B (Midmarket Edition), including 10 gold medals, more than any other platform. The gold medals were awarded for Vision & Strategy, Ability to Execute, Customer Service & Support, Partner Ecosystem, Site Search, Sales & Channel Enablement, Total Cost of Ownership, Content & Data Management, Promotions Management and Transaction Management. The 12 medals in the Paradigm B2B (Enterprise Edition) included five gold medals for Vision & Strategy, Total Cost of Ownership, Sales & Channel Enablement, Site Search and Promotions Management. 'BigCommerce is particularly well-suited for enterprise and mid-market B2B companies looking for a value-priced, partner-centric, multitenant SaaS ecommerce solution that leverages an extensive open application marketplace to deliver robust functionality,' said Andy Hoar, chief executive officer at Paradigm B2B. 'Customers spoke highly of BigCommerce's commitment to the B2B space, extensive partner ecosystem, rich open application marketplace with robust APIs, and the ease with which the solution can be configured by a nontechnical user and replicated for use across other B2B business units.' Combine MethodologyFor the Combine report, Paradigm B2B selects all vendors to evaluate and only allows invited companies to participate. No vendors may pay for admission to or placement within the Combine. All evaluated vendors are given the same opportunity to present their company vision, product capabilities and roadmap, go-to-market strategies and tactics, partner ecosystem, and customer case studies. Paradigm B2B uses a robust scoring methodology to evaluate all vendors on a scale of 1 to 5 across 38 detailed and weighted criteria. Medals are awarded based on composite scores in 12 distinct categories. Special weighting is given to the 'voice of the customer' via market feedback that Paradigm B2B gathered directly from dozens of vendor partners and clients. The breakdown of award criteria includes: Strategic Pillars Ability to Execute Customer Service & Support Partner Ecosystem Total Cost of Ownership (TCO) Vision & Strategy Product Capabilities Content & Data Management Integrations, Operations & Infrastructure Marketplaces Promotions Management Sales & Channel Enablement Site Search Transaction Management and Integrations Download the ReportsDownload complimentary copies of both Paradigm B2B Combines to get a deep dive on the categories where BigCommerce placed Gold, Silver and Bronze: 2025 Paradigm B2B Combine Midmarket Edition 2025 Paradigm B2B Combine Enterprise Edition About BigCommerceBigCommerce (Nasdaq: BIGC) is a leading open SaaS and composable ecommerce platform that empowers brands, retailers, manufacturers and distributors of all sizes to build, innovate and grow their businesses online. BigCommerce provides its customers sophisticated professional-grade functionality, customization and performance with simplicity and ease-of-use. Tens of thousands of B2C and B2B companies across 150 countries and numerous industries rely on BigCommerce, including Coldwater Creek, Harvey Nichols, King Arthur Baking Co., MKM Building Supplies, United Aqua Group and Uplift Desk. For more information, please visit or follow us on X and LinkedIn. About Paradigm B2BDigital innovation produces an ever-changing, unpredictable, and challenging environment that can make or break a B2B company. To be successful today, B2B companies must transform archaic business practices and business models and fundamentally rethink how they interact with customers. Paradigm B2B's purpose is to help guide B2B companies through today's complex, digital-first environment. B2B companies need world-class strategies and roadmaps, as well as clearly differentiated customer experiences, in order to thrive in an increasingly disrupted commerce landscape. Paradigm B2B focuses on offering high-quality advice that's well-informed and immediately actionable. BigCommerce® is a registered trademark of BigCommerce Pty. Ltd. Third-party trademarks and service marks are the property of their respective owners. Media Contact:Brad Hempr@
Yahoo
14-07-2025
- Automotive
- Yahoo
My Plates Launches Two Letter Texas Plate Auction! Plate messages with only two-letters that offer one big statement!
Ready to turn heads with the shortest, coolest license plate on the road? My Plates just kicked off a brand-new online auction featuring 25 ultra-rare Texas license plate messages—each one made up of just two letters. AUSTIN, Texas, July 14, 2025 /PRNewswire-PRWeb/ -- My Plates Launches Two Letter Texas Plate Auction! Ready to turn heads with the shortest, coolest license plate on the road? My Plates just kicked off a brand-new online auction featuring 25 ultra-rare Texas license plate messages—each one made up of just two letters. Yep, you read that right. Just 2-Letters. A very rare combination indeed. With only two-letters, they're easy to remember, they make a bold statement and stand out from the usual random-letter-number combos. Up for grabs are a great selection of two-letter abbreviated messages including: JR (Junior) DR (Doctor) HQ (Headquarters) NJ (New Jersey) ON (Ontario) Other hot picks include PG, IE, MO, NA, KS & OJ. All super clean, super cool and easy to remember. The winning bidders will own each two-letter plate message for 5 years, with their choice of plate design (including My Plates new Premium Embossed backgrounds) and first dibs on renewing it at the state's then everyday pricing. That means once the message is won at auction, it could be gone forever! Auction Details: My Plates 2-LETTER Plate Auction dates: Begin Bid Date: Monday, June 30, 2025, at 12.01am. End Bid Date: Wednesday, August 6, 2025, at 8.00pm. Two-letter plate messages are exclusive, unique and extremely limited. Winning any of these 25 plate messages is an incredibly rare opportunity. All plate messages are offered for a 5-year term, with first right to renew, and are fully transferable. Winners can display their won message on any of the 100+ eligible My Plates Select designs, including My Plates new Premium Embossed designs. "This event is an outstanding opportunity for someone to secure one of these unique and easy-to-remember plate messages as their official Texas tag" says My Plates CEO, Steve Farrar. Unlike other regular Texas license plates, plates sold by My Plates at auction are legally transferable. The plate owner then has the right to sell the plate message to another person with the same ongoing rights or gift it to a family member or friend. Transferability also means these plates could make great investments. The auction is now active, and bids are being accepted. Texans wishing to bid can register at The auction will close on August 6, 2025. Media Contact Steve Farrar, MyPlates, 512-633-7978, marketing@ View original content to download multimedia: SOURCE MyPlates
